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woman. Wilkins echographic score was 7.8 [5; 10]. A grade 1 mitral regurgitation 
(MR) was found in 4 patients and a grade 2 MR in one woman. PMV was performed 
successfully in all cases. The mitral valve area increased from 1.04±0.11 cm 2 [0.9;1.2] 
to 1.9±0,17 cm 2 [1.8;2.2]. The mean transmitral gradient was reduced from 11.8±2.48 
mmHg [10;16] to 5±1.22 mmHg [3;6]. The mean systolic pulmonary artery pressure 
decreased from 50.6±5.63 mmHg [45;60] to 34.6±6.38 mmHg [30;40]. MR increased 
in 3 patients: it was a grade 2 MR aggravating a preexisting grade 1 MR. No maternal 
or fetal complication related to procedure was reported. Functional improvement 
was noted in all cases. Childbirth was occurred without incident in all our patients. 
Conclusion: During pregnancy, percutaneous mitral valvuloplasty could be 
considered as the treatment of choice for severe mitral stenosis which are refractory 
to medical treatment. It allows a frank functional improvement and a childbirth in 
good condition.
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Complications of repeat percutaneous mitral valvuloplasty
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Background: Percutaneous mitral valvuloplasty (PMV) has emerged as the 
procedure of choice in treatment of mitral stenosis and has proved effectiveness in 
cases of mitral restenosis after surgical commissurotomy Compared with surgery, PMV 
is associated with shorter hospital stays, reduced patient discomfort, and signifi cantly 
lower costs. However, it is unknown whether patients who developed symptomatic 
mitral restenosis after PMV may benefi t from repeat PMV (re-PMV) with safety. 
Objectives: This study was designed to evaluate the occurrence rate and the 
predictive factors for severe complications following re-PMV. 
Methods: Retrospective study from a series of 40 procedures of re-PMV with 
the Inoue balloon at 8±4 years after prior procedure, performed between 1996 and 
2011. A clinical and ultrasound follow-up was achieved in 31 patients with a mean 
follow-up period of 43±26 months. 
Results: The mean age of patients was 43±11 years [23, 63]. 87.5% of the 
population being female (5 men and 35 women). The immediate procedural success 
was achieved in 31 patients (77.5%). A severe mitral regurgitation (MR) was observed 
in 3 patients (7.5%). A cerebrovascular stroke occurred in 1 patient (2.5%). No 
procedure-related death or cardiac tamponade were noted. Only a left atrial area ≤25 cm2 
was linked to high risk of severe MR.
At long-term, mitral restenosis was observed in 13 patients (42%) at 53±30 
months [9; 128] after re-PMV, 2 patients presented thromboembolic events (6%) and 
no death. Only the male had been identifi ed as a predictor of restenosis 
Conclusion: The feasibility of re- PMV with a relatively high procedural success 
rate and an acceptable complication profi le makes it an appealing therapeutic strategy 
for patients with recurrent valve stenosis. The improved experience of our medical 
teams, and the systematic use of transoesophageal echocardiography to detect thrombi 
explain the low incidence of the complications of re-PMV in our study. 
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Repeat percutaneous mitral valvuloplasty in patients aged 50 years and more
Saoussen Antit, Sana Fennira, Sana Sioua, Yacine Ellouze, Sondos Kraiem
Hôpital Habib Thameur, Tunis, Tunisie
Background: The management of postintervention (surgery or balloon commis-
surotomy) mitral valve restenosis is controversial and remains a clinical challenge. 
It is unknown if elderly patients who developed symptomatic mitral restenosis after 
PMV may benefi t from repeat percutaneous mitral valvuloplasty (re-PMV).
Purpose: the aim of this study is to evaluate the safety and effi cacy of re-PMV 
for the treatment of mitral restenosis in patients aged 50 years and more.
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New insights on the role of serotonergic 5-HT2B receptors in drug-induced 
valvulopathy: contribution of endothelial cells?
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Cardiac valve remodelling has been associated with chronic use of serotonergic 
5-HT2B receptors agonists such as nordexfenfl uramine (NDF), ecstasy or pergolide, but 
the pharmacological mechanisms have not been clearly understood. Histopathological 
lesions show cell proliferation with extracellular matrix deposition that can drive to 
valvular leafl ets stenosis, severe cardiac insuffi ciency and surgical valve replacement. 
In this work, we developed and standardized an in vivo mouse model that mimics 
5-HT2B receptor agonists-induced valve degeneration. Adult male 129sv mice (aged 
12 weeks) were rando mLy assigned in 6 different groups and underwent a subcutaneous 
micro-osmotic pump implantation delivering the highly selective 5-HT2B receptors 
agonist, 1mg/kg/day NDF or vehicle (sterile water) for 4 weeks. Four groups of 10 
wild-type mice were designed: 1) vehicle, 2) NDF, 3) NDF/L-NAME (300 mg/ kg/ day), 
4) NDF/ritanserine (2mg/kg/day) and two groups of transgenic 5-HT2B 
-/- mice: 5) 
vehicle and 6) NDF. Mice were monitored by regular body weight, blood pressure 
measurement and echocardiography. At the end of the experiment, we point out 
a signifi cant increase of urinary amount of 5-HIAA (52±7 μg/L vs 74±5μg/L). 
Histological analysis of the hearts reveals increased mitral valve leafl ets thickness 
(35±6 μM vs 60±6 μM) and cellularity (endothelial or interstitial) in NDF group 
(+20% vs control). These histological lesions are prevented in part by a co-treatment 
with ritanserine or surprisingly fully by L-NAME. Transgenic KO 5-HT2B 
-/- mice do 
show any response to NDF stimulation. In conclusion, we demonstrate the crucial 
role of 5-HT2B receptors in NDF induced valvulopathy and that the lesions are made 
in part by endothelial cells proliferation depending on nitric oxide signalling pathway. 
Keywords: valvulopathy; serotonin; 5-HT2B receptors; endothelium; nitric oxide.
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Percutaneous mitral valvuloplasty during pregnancy
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Introduction: Pregnancy is one of the most important factors known to destabilize 
valvular heart disease. In particular, pregnancy is a major cause of aggravation in 
the clinical course of women with mitral stenosis (MS). Surgical treatement of MS 
during pregnancy may be hazardous for both mother and foetus. In this context, 
percutaneous mitral valvuloplasty (PMV) using the Inoue balloon may constitute a 
particularly attractive alternative to surgery. We report the results of PMV achieved 
in a series of 5 pregnant women. 
Purpose of work: The purpose of this study was to evaluate the effectiveness 
of PMV in pregnant women. 
Methods: From 2005 to 2011, 5 pregnant women underwent PMV using Inoue 
balloon. A clinical, echocardiographic, hemodynamic assessment was analyzed pre 
and post procedure.
Results: The mean age was 29 years [25; 33]. The average length of pregnancy 
was 32.67 weeks [28; 40]. Four women were symptomatic with dyspnea class III of 
NYHA and one woman was in class II of NYHA. Atrial fi brillation was noted in one 
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Impact of percutaneous mitral valve commissurotomy on right ventricular 
function
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Introduction: The right ventricular function is an important determinant of clinical 
symptoms, exercise capacity, pre-operative survival and post-operative outcome in 
patients with mitral stenosis (MS).
Objectif: The aim of this work was to evaluate the impact of percutaneous mitral 
commissurotomy (PMC) on right ventricular function (RV) in patients with severe mitral 
stenosis managed in Center of cardiology- University Hospital IBN Rochd-Casablanca.
Methods and Results: Of 150 patients there were 20 men and 130 women, their 
mean age was 35±10 years. One hundred were in New York Heart Association class 
II, 40 in class III and 10 in class IV. Eighty patients with atrial fi brillation.
Were studied before and after PMC. Multiple parameters of global and longitudinal 
RV function were assessed by conventional and tissue Doppler imaging echocardio-
graphy. Mitral surface area and hemodynamic parameters improved signifi cantly after 
PMC; mean left atrial pressure fell from 18.76±6.18 to 10.65±4.38 mmHg (p<0.001), 
mean transmitral gradient from 14.03±4.70 to 4.63±2.05mmHg (p<0.001) and mitral 
valve area from 0.99±0.22 to 1.88±0.41cm2 (p<0.001), in the RV Tei index from 
0.44+0.025 to 0.29+0.17 (P 1/4 0.021), in myocardial acceleration during isovolumic 
contraction (IVA) at the lateral tricuspid annulus from 0.36+0.11 m/s2 to 0.25+0.07 
m/s2 (P 1/4 0.023), and in isovolumic contraction velocities at the lateral tricuspid 
annulus from 11.03+3.37cm/s to 8.50+2.04cm/s (P 1/4 0.034).
Conclusion: This study demonstrates that, in patients with MS, global right 
ventricular function improves in the majority of patients. 
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Accuracy of mitral valve planimetry assessed from trans-thoracic real-time 
3-dimensional echocardiography
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Background: Mitral valve planimetry obtained from a transverse parasternal view 
may be particularly challenging, even with the use of a 3-Dimensional (3D) biplane 
imaging. This issue may be resolved by trans-thoracic echocardiography using real-time 
full volume 3D datasets that allow mitral valve planimetry from the apical view.
Methods: This study included 45 patients (62% women, aged 65±18 years, 
49% degenerative etiology) referred for mitral valvular stenosis assessment. Mitral 
valve area computed from real-time 3D datasets (apical views) was compared to the 
results of 2D planimetry (parasternal transverse view), proximal isovelocity surface 
area (PISA), the continuity equation and patient’s clinical status. For functional status 
asssessment, the following events were considered: 1) previous heart failure, 2) systolic 
pulmonary hypertension defi ned by systolic pulmonary artery pressure >50mmHg at 
rest or >60mmHg during exercise, 3) consensual decision to refer patient to cardiac 
surgery or mitral valve dilatation.
Results: Mitral valve area assessed from real time 3D planimetry was feasible in 95% 
of patients (100% [n=23/23] for rheumatic and 91% [n=20/22] for degenerative etiology), 
while the feasibility by 2D was 69% (87% for rheumatic and 69% for degenerative 
etiology) and 91% for PISA and continuity equation. Mitral valve area obtained from 3D 
planimetry correlated with 2D planimetry (r=0.64, p<0.0001), PISA (r=0.63, p<0.0001) 
and the continuity equation (r=0.75, p<0.0001). Interestingly, 94% (Se=94%, Spe=62%, 
PPV=91%, NPV=71%, concordance=88%) of patients with signifi cant mitral valve stenosis 
(1.5 cm2) by real time 3D were symptomatic versus 79% (Se=79%, Spe=85%, PPV=95%, 
NPV=55%, concordance=80%) by 2D planimetry. Finally, inter-observer reproducibility 
for real time 3D planimetry was excellent (0.1±0.16 cm2, 8%).
Conclusion: Trans-thoracic real time 3D planimetry obtained the from apical 
view provides an accurate and reproducible assessment of mitral valve area, fairly 
related to other methods and patient’s clinical status. 
Methods: Retrospective study from a series of 40 procedures of re-PMV with 
the Inoue balloon at 8±4 years after prior procedure, performed between 1996 and 
2011. The procedural success was defi ned by a mitral valve area ≥1.5 cm 2 and a 
grade ≤2 mitral regurgitation.
Results: 13 patients were ≥50 years old (32.5%). The mean age was 56 years 
[50;63]. There were 3 men and 10 women. Five patients were symptomatic with 
dyspnea class III of NYHA and the others (8) were in class II of NYHA. Nine patients 
were in atrial fi brillation. The mean Wilkins score was 8.5 [7; 13]. 6 patients had a 
Wilkins score ≥9. The mean Padial score was 9.2 [5; 13]. 8 patients had a Padial score 
≥9. Ten patients had mitral regurgitation (MR). It was a grade 1 MR. The immediate 
procedural success was achieved in 10 patients. After re-PMV the mitral valve area 
increased from 1.23±0.13 cm2 to 1.73±0.38 cm2, the transmitral gradient decreased 
from 8.76±3.26 mmhg to 3.9±2.72 and the mean systolic pulmonary artery pressure 
decreased from 40.9±8.42 mmHg [25; 60] to 35±9.04 mmHg [25;50]. A severe MR 
was observed in one patient. A cerebrovascular stroke occurred in 1 patient. No death 
or cardiac tamponade were noted. At long term, restenosis was observed in 4 (out 
of 10) patients at 52.25±15.90 months. 3 patients had mitral valve replacement and 
one patient underwent a re-PMV. Only one patient had presented a thromboembolic 
event and no death. 
Conclusion: Repeat percutaneous mitral valvuloplasty in elderly patients with 
restenosis after a prior percutaneous valvuloplasty is feasible and can be accomplished 
with acceptable morbidity and mortality. It might serve as an acceptable approach to 
avoid surgery in elderly patients with high operative risk.
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Background: Symptomatic mitral restenosis develop in 7% to 40% of patients 
after percutaneous mitral valvuloplasty (PMV). Currently, most of these patients are 
referred for mitral valve replacement. However, it is unknown if these patients may 
benefi t from repeat PMV (re-PMV).
Purpose: The purpose of this study is to assess the immediate and long-term 
results of the re-PMV and analyze the different clinical and laboratory fi ndings to 
determine predictors of outcome of re-PMV.
Methods: Retrospective study from a series of 40 procedures of re-PMV with 
the Inoue balloon at 8±4 years after prior procedure, performed between 1996 and 
2011. A clinical and ultrasound follow-up was achieved in 31 patients with a mean 
follow-up period of 43±26 months. 
Results: The mean age of patients was 43±11 years [23, 63]. 87.5% of the 
population being female (5 men and 35 women). The immediate procedural success 
was achieved in 31 patients (77.5%). A severe mitral regurgitation (MR) was observed 
in 3 patients (7.5%). A cerebrovascular stroke occurred in 1 patient (2.5%). No 
death or cardiac tamponade were noted. Class III or IV of NYHA, a pre-procedural 
MR, pulmonary hypertension and a Padial score >10 were identifi ed as predictors 
of failure. More the score of Wilkins is high (>8), more it is predictive of failure. 
The two components of the Wilkins score: valvular mobility and subvalvular 
apparatus (SVA) and the parameter of the redesign of the SVA score of Padial 
considered separately are also predictive of failure. Only a left atrial area ≤25 cm 
2 was linked to high risk of severe MR. At long-term, most patients (84%) had no 
functional impairment, the mean mitral valve area was 1.5±0.33 cm2 [0.9; 2.2], 
mitral restenosis was observed in 13 patients (42%) at 53±30 months [9; 128] after 
re-PMV. 9 patients had mitral valve replacement (32%), 4 patients underwent a 
re-PMV (13%), 2 patients presented thromboembolic events (6%) and no death. 
Only the male had been identifi ed as a predictor of restenosis. 
Conclusion: Re-PMV is a therapeutic alternative to surgery that is effective and 
promising interesting immediate and long term results analysis of clinical and mainly 
echographic parameters is useful for predicting the success of the gesture, which will 
allow a better selection of candidates for re-PMV.
